The U.S. Food and Drug Administration suspended enrollment for all clinical trials of the EZH2 inhibitor tazemetostat following a report that a pediatric patient participating in a phase I study developed a secondary lymphoma.
According to a statement from Epizyme, the drug’s manufacturer, “At the time of the safety report, the patient had been on study for approximately 15 months and had achieved a confirmed partial response. This patient has now discontinued tazemetostat and is being treated for T-cell lymphoma.”
The EZH2 inhibitor is being studied as a monotherapy in ongoing phase I and II trials of follicular lymphoma and diffuse large B-cell non-Hodgkin lymphoma.
Source: Endpoint News, April 23, 2018; Epizyme press release, April 23, 2018.